3F8

3F8 is a monoclonal antibody used in the treatment of neuroblastoma, a type of cancer that arises from nerve tissue. This antibody specifically targets the GD2 antigen, which is highly expressed on the surface of neuroblastoma cells.

Mechanism of Action

3F8 works by binding to the GD2 antigen on the surface of neuroblastoma cells. This binding triggers an immune response, leading to the destruction of the cancer cells. The immune response is primarily mediated by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Clinical Use

3F8 has been used in clinical trials and treatments primarily for patients with high-risk neuroblastoma. It is often administered in combination with other treatments such as chemotherapy, radiation therapy, and stem cell transplantation to improve outcomes.

Side Effects

The administration of 3F8 can lead to several side effects, including:

• Pain at the site of infusion
• Fever
• Hypertension
• Allergic reactions

Research and Development

3F8 was developed by researchers at Memorial Sloan Kettering Cancer Center. Ongoing research aims to improve the efficacy and reduce the side effects of this treatment. Newer versions and derivatives of 3F8 are also being explored.

See Also

• Neuroblastoma
• Monoclonal antibody therapy
• GD2
• Antibody-dependent cellular cytotoxicity
• Complement-dependent cytotoxicity